---
created: 2025-04-13
updated: 2025-04-13T10:53
id: Ql?6Y{4q9x
specialty: pharmaco
specialty_id: 481
tags:
  - source/ak-original-decks::step-1::lolnotacop::drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::20-erlotinib
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::imatinib-dasatinib-nilotinib-dabrafenib-vemurafenib
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::21-erlotinib
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::erlotinib
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::01-imatinib,-erlotinib,-sorafenib,-sunitinib,-vemurafenib"
type: flashcard
---

# Question
Erlotinib is a first-line treatment of **non-small cell lung** cancer

---

# Answer
EGFR tyrosine kinase inhibitor